Antibody-drug conjugate · Cytotoxic, directed at fibronectin EDB splice variant (EDB-FN) (FN1) · developed by Pyxis Oncology
Micvotabart pelidotin is an antibody-drug conjugate that pairs a fully human IgG1 antibody against the extra domain B splice variant of fibronectin with the cytotoxic auristatin derivative Aur0101 via a cleavable linker. The antibody binds EDB-FN in the tumor stroma, releasing the payload, which inhibits microtubule polymerization and kills nearby tumor cells, fibroblasts and tumor vasculature. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06795412 | Phase 1/2 | Advanced Solid Tumors | Recruiting | PYXS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
Updated Oct 25, 2026. Something wrong or missing? Report it on the PYXS page.
See PYXS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PYXS catalysts and pipeline →